Key result
A 3-month course of sacubitril/valsartan significantly improved mean left ventricular ejection fraction from 27.65% at baseline to 32.89% (P<0.001) in patients with HFrEF.
Why the study?
Data were lacking on the effects of sacubitril/valsartan on cardiac functions and left ventricular reverse remodeling assessed by 3D echocardiography.
Does sacubitril/valsartan improve left ventricular dynamic functions and reverse remodeling assessed by 3D echocardiography in patients with HFrEF?
Cohort (n=100)
No
Does sacubitril/valsartan improve left ventricular dynamic functions and reverse remodeling assessed by 3D echocardiography in patients with HFrEF?
Absolute Event Rate: 32.89% vs 27.65%
p-value: p=<0.001
Short-term treatment with sacubitril/valsartan significantly improves left ventricular systolic function and promotes reverse remodeling in HFrEF patients, as demonstrated by 3D echocardiography.
Short-term sacubitril/valsartan was associated with LVEF gains in HFrEF; hypothesis-generating and leaves open causal confirmation in randomized trials.
BACKGROUND: Three-dimensional (3D) echocardiography and 3D strain parameters have been used for a comprehensive quantitative assessment of left ventricular (LV) myocardial dynamics. So far, there are no data on sacubitril/valsartan effects on cardiac functions and LV reverse remodeling using 3D echocardiography. This study aimed to evaluate the effects of sacubitril/valsartan on the LV functions using two-dimensional (2D) echocardiography, 3D echocardiography, and the 3D strain parameters. METHODS: A single-center prospective cohort study which included 100 heart failure with reduced ejection fraction (HFrEF) patients with guidelines-approved indications for sacubitril/valsartan treatment. Patients received a short course (3-month) of sacubitril/valsartan. 3-month follow-up 2D, 3D echocardiographic parameters, and 3D strain were compared to baseline parameters. RESULTS: The results of the study revealed a significant improvement in left ventricular dynamic functions at 3-month follow-up with an improvement in left ventricular systolic function (mean left ventricular ejection fraction (LVEF) increased from 27.65±4.98% to 32.89±6.03%, P<0.001). Comparison of HFrEF patients with ischemic and non-ischemic etiologies showed that echocardiographic parameters significantly improved in both groups after 3 months of sacubitril/valsartan treatment. There was no statistically significant difference between both groups regarding echocardiographic parameters at baseline and 3-month follow-up. CONCLUSIONS: In a single-center prospective observational cohort study evaluating the effects of short-term (3-month course) sacubitril/valsartan treatment on LV dynamics assessed by 3D echocardiography and 3D strain, sacubitril/valsartan was associated with a significant improvement of LV systolic functions and reverse remodeling effects in both ischemic and non-ischemic HFrEF patients.
No takes yet. Share an insight, caveat, or question.
Öz et al. (2021) conducted a cohort in Heart failure with reduced ejection fraction (HFrEF) (n=100). sacubitril/valsartan vs. baseline was evaluated on mean left ventricular ejection fraction (LVEF) (p=<0.001). A 3-month course of sacubitril/valsartan significantly improved mean left ventricular ejection fraction from 27.65% at baseline to 32.89% (P<0.001) in patients with HFrEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: